Agilent Technologies (UK)
Agilent Technologies (UK) have entered into partnership with Imperial College London through the loan of a state-of-the-art Time of Flight Machine. The cutting edge analytical solutions will be used for studies of Mycobacterium tuberculosis (Mtb), the bacteria that causes tuberculosis. Tuberculosis is currently the world’s deadliest infectious disease with cases of multidrug-resistant TB having risen to 580,000 globally.
Benefits to Imperial and Agilent Technologies (UK)
The Agilent 6545 Q-TOF Mass Spectrometer features a unique ‘fragile ion’ tune, allowing the most unstable of molecules to be structurally preserved, allowing the behaviour of bacteria to be tracked, revealing and identifying key metabolites, enzymes and pathways that will increase our knowledge and considerably help to design better antibiotics.
Professor David Holden, Director of the MRC CMBI commented “We are very grateful indeed to the Faculty of Natural Sciences and Agilent for enabling this metabolomics research, which has great potential - not only for Dr. Larrouy-Maumus’ research on mycobacteria but also for work on many other bacterial pathogens”.
Head of the Department of Life Sciences Murray Selkirk concurred, reflecting that “…the instrumentation will allow us to answer questions which would otherwise be impossible and progress the research field.”
“This project exemplifies what can be achieved when we form deep partnerships with our colleagues in the industrial sector,” said Tom Welton, Dean of the Faculty of Natural Sciences and controller of the Kick-start fund so important to this project’s success. “We are very grateful for Agilent’s generous support of this vital research.”
On behalf of Agilent, Dr Anthony Sullivan (LC/MS Product Specialist) said, “We are delighted to see our partnership with Imperial developing in this way – with powerful solutions in the hands of highly talented and determined researchers”.
Benefits to the wider public
While Dr. Larrouy-Maumus’ research focuses specifically on the process of tuberculosis infection, he says the technology that the instrument utilises is important for the field as a whole. “Bacterial infections and antimicrobial resistance represent a worldwide threat that needs multidisciplinary research associated with the latest technologies” he says. “Using a powerful metabolomics approach gives us a unique opportunity to identify the key metabolic pathways and enzymes that could be the targets of future drugs. Not only is the Agilent 6545 Q-TOF the best suited equipment for this application, the accompanying software solutions developed by Agilent (VistaFlux, ProFinder and MPP) make it easy to deal with the massive amount of data.”
Text lifted from the article, Agilent join Imperial's fight against TB and antimicrobial resistance, published on 01 December 2016.